Related Experiment Video

Updated: Mar 8, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights

Ricardo Costa1, Ami N Shah2, Cesar A Santa-Maria3

  • 1Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Chicago, USA.

Cancer Treatment Reviews
|January 21, 2017
PubMed

Insights

Triple negative breast cancer (TNBC) lacks targeted therapies, despite EGFR expression in most patients. This review explores EGFR pathway biology, clinical trials, and future therapeutic strategies for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Triple negative breast cancer (TNBC) represents 10-20% of all breast cancer cases.
  • TNBC lacks targeted therapies, unlike hormone receptor-positive and HER2-positive breast cancers.
  • Most TNBC tumors express the Epidermal Growth Factor Receptor (EGFR).

Purpose of the Study:

  • To review recent discoveries in EGFR pathway biology specific to TNBC.
  • To summarize the clinical progress of EGFR-targeted therapies in TNBC.
  • To propose rational future investigational therapeutic approaches for TNBC.

Main Methods:

  • Literature review of recent discoveries in EGFR pathway biology.
  • Analysis of clinical trial data for EGFR-targeted agents in TNBC.
  • Synthesis of current knowledge to suggest future therapeutic strategies.

Main Results:

  • Early clinical trials of EGFR-targeted monoclonal antibodies and tyrosine kinase inhibitors showed limited success in TNBC.
  • The underlying biology of the EGFR pathway in TNBC is complex and requires further elucidation.
  • Despite challenges, the EGFR pathway remains a potential target for novel TNBC therapies.

Conclusions:

  • Targeted therapies for TNBC are urgently needed.
  • Further research into the EGFR pathway's role in TNBC is crucial.
  • Developing novel therapeutic strategies targeting the EGFR pathway holds promise for improving TNBC treatment outcomes.
Keywords:
Epidermal Growth Factor ReceptorTargeted therapyTriple negative breast cancermTOR

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

803
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.0K